ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO296

Outcomes of Australian and New Zealand Dialysis and Transplant Patients with Kidney Failure Attributed to Kidney Stones

Session Information

Category: Bone and Mineral Metabolism

  • 502 Bone and Mineral Metabolism: Clinical


  • Cheikh Hassan, Hicham I., University of Wollongong Faculty of Science Medicine and Health, Wollongong, New South Wales, Australia
  • Tunnicliffe, David J., The Children's Hospital at Westmead, Westmead, New South Wales, Australia
  • Lloyd, Lyn, Auckland City Hospital, Auckland, Auckland, New Zealand
  • Yip, Adela, The University of Sydney, Sydney, New South Wales, Australia
  • Cashmore, Brydee, The Children's Hospital at Westmead, Westmead, New South Wales, Australia
  • Mullan, Adam W.F., The University of Auckland, Auckland, New Zealand
  • Jose, Matthew D., Royal Hobart Hospital, Hobart, Tasmania, Australia
  • Mallett, Andrew John, Townsville Hospital and Health Service, Townsville, Queensland, Australia

Prevalence of kidney stones in the general population can reach 15-20%. Kidney stone formers (KSF), compared to non-KSF, have an increased risk of developing chronic kidney disease and kidney failure (KF). While risk factors, aetiology and outcomes in KSF is well established there remains little data for patients after they develop KF. We therefore set out to examine outcomes of KSF with KF (transplant or recieving dialysis).


Using the Australian and New Zealand Dialysis and Transpant (ANZDATA) registry we included adult patients with KF who recieved dialysis or transplant (1973-2020). We divided our cohort into KSF and non-KSF groups. For dialysis, we included haemodialysis and peritoneal dialysis to determine risk of mortality. A joinpoint model examined annual rates of KSF diagnosed with KF over time. A seperate analysis was conducted for transplant recipients to examine risk of mortaity and graft failure. Multivariate Cox regression analysis was used to determine hazard ratio (HR) and 95% confidence interval (CI) of outcomes.


In the dialysis cohort 79,670 patients were followed (293,255 patient-years) with 871 (1.1%) having KF from calculi. Compared to non-KSF the KSF group were less likely to have diabetes (26%vs45%) or vascular disease (17%vs45%) and were older (61vs58 years), P<0.001. Proportion of KF with calculi as a cause declined annually by 2.7% (95%CI 1.9-7.4, P<0.01). There was no difference in mortality between KSF and non-KSF in patients in multivariate analysis (HR 0.93, 95%CI 0.86- 1.01, P<0.001).

In the transplant cohort 25,052 patients were included, with 219 (0.9%) having KF from calculi. Pre-emptive transplant occurred in 2,221 (2.7%) of the whole group but only in 12 (1.3%) of KSF. Compared to the non-KSF the KSF group were less likely to be diabetic (20%vs12%) and older (48 vs 51 years) (P<0.001). There was no difference in mortality risk (HR 1.04, 95%CI 0.86-1.26) or graft failure (HR 1.01, 95%CI 0.77-1.34) between the two groups in multivariate analysis.


In Australia and New Zealand, KSF as a cause of KF is rare and declining over time. There is no difference in mortality risk between KSF and non-KSF in patients who start dialysis, or a difference in graft failure rate in those who received a transplant.